Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410879" target="_blank" >RIV/00216208:11130/20:10410879 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/20:10410879

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MHG_JGEbI_" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MHG_JGEbI_</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/2162402X.2019.1703449" target="_blank" >10.1080/2162402X.2019.1703449</a>

Result language

angličtina

Original language name

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

Original language description

The term &apos;immunogenic cell death&apos; (ICD) denotes an immunologically unique type of regulated cell death that enables, rather than suppresses, T cell-driven immune responses that are specific for antigens derived from the dying cells. The ability of ICD to elicit adaptive immunity heavily relies on the immunogenicity of dying cells, implying that such cells must encode and present antigens not covered by central tolerance (antigenicity), and deliver immunostimulatory molecules such as damage-associated molecular patterns and cytokines (adjuvanticity). Moreover, the host immune system must be equipped to detect the antigenicity and adjuvanticity of dying cells. As cancer (but not normal) cells express several antigens not covered by central tolerance, they can be driven into ICD by some therapeutic agents, including (but not limited to) chemotherapeutics of the anthracycline family, oxaliplatin and bortezomib, as well as radiation therapy. In this Trial Watch, we describe current trends in the preclinical and clinical development of ICD-eliciting chemotherapy as partner for immunotherapy, with a focus on trials assessing efficacy in the context of immunomonitoring.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30102 - Immunology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

OncoImmunology [online]

ISSN

2162-402X

e-ISSN

—

Volume of the periodical

9

Issue of the periodical within the volume

1

Country of publishing house

US - UNITED STATES

Number of pages

23

Pages from-to

1703449

UT code for WoS article

000506423300001

EID of the result in the Scopus database

2-s2.0-85077601399